Won-Seog Kim

Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium.

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Re...

Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B...

Golidocitinib (selectieve JAK1-remmer) bij refractair/recidief perifeer T-cellymfoom

Totale overleving met brentuximab vedotin bij stadium III-IV hodgkinlymfoom: ECHELON-1 OS definitief

Alisertib versus investigator's choice bij recidief/refractair perifeer T-cellymfoom: fase III

CT-P10 rituximab-biosimilar bij eerder onbehandeld DLBCL: fase III vergelijkende studie